MUCOSAL PLANTIBODIES--A HUMAN ANTIHSV SIGA

总体目标是开发基于抗体的技术， 用于预防性传播的消费品 性病（STDs）。 一个小体积的凝胶，提供24小时的性病 保护可以像其他基于消费者的产品一样使用， 每天使用一次或根据需要使用。良好的效力和 抗体的特异性使它们成为谨慎使用的理想试剂， 女性或与润滑剂结合使用。 具体目标是 建议旨在确定安全性，有效性和 抗体产品的可接受性。 拟议的研究将： (a)测量局部施用的抗体在细胞中的滞留半衰期， 人阴道;（B）以低成本、高成本、低成本的方式开发第一种人SIgA， （c）确定抗HSV 2 植物体在离体分泌物中是稳定的， 当单独使用时以及当与市售可得的 阴道制剂和性润滑剂;（d）确定小鼠是否吸收 通过直接测量血清中的植物体和 间接通过测量全身和粘膜小鼠抗植物体。 拟定商业应用： 基于抗体的技术现在正在实现系统性 治疗，但一个未开发的抗体的商业应用， 粘膜预防。 阴道杀菌剂是一种重要的 粘膜抗体的应用，但该技术是如此灵活， 它很容易扩展到预防病原体引起的疾病 在其他粘膜部位。

The overall goal is to develop antibody-based technology that can be used in consumer products for the prevention of sexual transmission of diseases (STDs). A small volume gel that provides 24 hours of STD protection could be used much like other consumer-based products that are used once a day or as needed. The well-established potency and specificity of antibodies make them ideal agents for discreet use by women or in combination with lubricants. The specific aims of this proposal are designed to determine the safety, efficacy and acceptability of antibody-based products. The proposed studies will: (a) measure the residence half time of a topically applied antibody in the human vagina; (b) develop the first human SIgA in a low cost, high capacity production system; (c) determine if anti-HSV2 plantibodies are stable in ex vivo secretions and are efficacious in vivo when used alone and when combined with a commercially available vaginal formulation and a sexual lubricant; (d) determine if mice absorb SIgA plantibodies by direct measurement of plantibodies in serum and indirectly by measurement of systemic and mucosal mouse anti-plantibody. PROPOSED COMMERCIAL APPLICATION: Antibody-based technology is now coming to fruition for systemic therapeutics, but an untapped commercial applications for antibodies are in mucosal prevention. Vaginal microbicides is one important application for mucosal antibodies but the technology is so flexible that it is readily extended to the prevention of diseases by pathogens at other mucosal sites.